Autoimmune Encephalitis clinical trials at UCSF
1 research study open to eligible people
Autoimmune encephalitis is a condition where the immune system mistakenly attacks the brain. UCSF is conducting a study to understand the effects of Satralizumab on patients with NMDAR or LGI1 encephalitis. We are evaluating its safety, how it works, and how it travels within the body.
Showing trials for
Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis
open to eligible people ages 12 years and up
The purpose of this study is to assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of satralizumab in participants with anti-N-methyl-D-aspartic acid receptor (NMDAR) and anti-leucine-rich glioma-inactivated 1 (LGI1) encephalitis.
San Francisco, California and other locations
Last updated: